Related Experiment Video
Updated: Jul 12, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
The pathophysiology and burden of restenosis
1Department of Cardiology and Christiana Center for Outcomes Research, Christiana Care Health Services, Newark, Delaware 19718, USA. WWeintraub@Christianacare.org
Insights
Percutaneous transluminal coronary angioplasty (PTCA) can lead to restenosis. Drug-eluting stents and pharmacotherapy show promise in reducing restenosis risk, especially for high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomedical Engineering
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) has transformed coronary artery disease treatment.
- Restenosis, the re-narrowing of arteries, remains a significant complication after PTCA, occurring in 30%-50% of balloon angioplasty cases and 10%-30% of stenting procedures.
- Restenosis is understood as a biological response to the injury caused by PTCA procedures.
Purpose of the Study:
- To review the incidence and mechanisms of restenosis following coronary angioplasty.
- To evaluate the efficacy of different stenting strategies, including bare-metal and drug-eluting stents, in managing restenosis.
- To explore the potential of pharmacologic management in conjunction with stenting to mitigate restenosis.
Main Methods:
- Review of animal and human data on restenosis mechanisms.
- Analysis of clinical studies comparing bare-metal stents (BMS) and drug-eluting stents (DES).
- Evaluation of recent findings on the pharmacologic treatment of restenosis.
Main Results:
- Bare-metal stents can promote intimal hyperplasia due to immune and proliferative responses.
- Drug-eluting stents, utilizing anti-inflammatory or antiproliferative agents, significantly reduce the risk of restenosis.
- Selective use of DES in high-risk populations is cost-effective and clinically beneficial compared to BMS.
- Emerging evidence supports the feasibility of pharmacologic management for restenosis.
Conclusions:
- Restenosis following PTCA is a complex response to injury, necessitating advanced treatment strategies.
- Drug-eluting stents and judicious use of oral pharmacotherapy offer improved long-term outcomes by reducing restenosis rates.
- Optimizing treatment involves selective application of DES and integrating pharmacologic interventions, particularly for high-risk patients.
Abstract:
The introduction of percutaneous transluminal coronary angioplasty (PTCA) revolutionized the surgical treatment of coronary artery disease. However, despite increased surgical experience and technical breakthroughs, restenosis occurs in 30%-50% of patients undergoing simple balloon angioplasty and in 10%-30% of patients who receive an intravascular stent. Animal and human data indicate that restenosis is a response to injury incurred during PTCA. The need for reintervention in a high percentage of patients due to restenosis remains an important limitation to the long-term success of PTCA. Stenting reduces initial elastic recoil and limits negative arterial remodeling; however, bare-metal stents may promote intimal hyperplasia by eliciting an immune and proliferative response. Consistent with these data, clinical studies suggest that drug-eluting stents, coated with anti-inflammatory or antiproliferative agents, reduce the risk for restenosis. Stenting represents a considerable cost burden. Treatment strategy should focus on selective use of expensive drug-eluting stents in populations where they have been found to be more clinically effective than bare-metal stents--patients who are at high risk for restenosis or who develop restenosis with bare-metal stents. Recent studies suggest that the pharmacologic management of restenosis is now feasible. Together, the judicious use of stents and oral pharmacotherapy promise to reduce the risk for restenosis, even among high-risk patients.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:30Peripheral Artery Disease I: Introduction
01:17Pathophysiology of Heart Failure
01:30Atherosclerosis I: Introduction
01:15Aortic Regurgitation I: Introduction
01:27Peripheral Artery Disease III: Interprofessional Care